 Aromatase inhibitors (such as exemestane and anasatrozole) may be more effective than selective estrogen receptor modulators (such as tamoxifen) at reducing breast cancer risk and they are not associated with an increased risk of endometrial cancer and thromboembolism.The management of breast cancer depends on various factors, including the stage of the cancer and the person's age.Treatments are more aggressive when the cancer is more advanced or there is a higher risk of recurrence of the cancer following treatment.